/In Peer-Reviewed Journals

Asthma

Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population

Kerkhof M, Tran TN, Soriano JB, Golam S, Gibson D, et al.
Thorax 2017.
[Full Text]

Lack of asthma and rhinitis control in general practitioner-managed patients prescribed fixed dose combination therapy in Australia

Bosnic-Anticevich S, Kritikos V, Carter V, Yan KY, Armour C, et al.
J Asthma 2017; 8: 1-11.
[PubMed] [Full Text]

Asthma referrals: a key component of asthma management that needs to be addressed

Price D, Bjermer L, Bergin DA, Martinez R.
J Asthma Allergy 2017; 10: 209-223.
[Full Text]

Initiating or changing to a fixed-dose combination of fluticasone propionate/formoterol over fluticasone propionate/salmeterol: a real-life effectiveness and cost impact evaluation

Wan Yau Ming S, Haughney J, Small I, Wolfe S, Hamill J, et al.
Respir Med 2017; 129: 199-206.
[Full Text]

Real-life effectiveness and safety of the inhalation suspension budesonide comparator vs the originator product for the treatment of patients with asthma: a historical cohort study using a US health claims database

Price DB, Gefen E, Gopalan G, Miglio C, McDonald R, et al.
Pragmat Obs Res 2017; 8: 69-83.
[PubMed] [Full Text]

Medication-related costs of rhinitis in Australia: a NostraData cross-sectional study of pharmacy purchases

Smith P, Price D, Harvey R, Carney AS, Kritikos V, et al.
J Asthma Allergy 2017; 10: 153-61.
[PubMed] [Full Text]

Does co-payment for inhaler devices affect therapy adherence and disease outcomes? A historical, matched cohort study

Voorham J, Vrijens B, van Boven JF, Ryan D, Miravitlles M, et al.
Pragmat Obs Res 2017; 8: 31-41.
[PubMed] [Full Text]

A randomized pragmatic trial of changing to and stepping down fluticasone/formoterol in asthma

Usmani OS, Kemppinen A, Gardener E, Thomas V, Konduru PR, et al.
J Allergy Clin Immunol Pract 2017; 5(5): 1378-1387.e5.
[PubMed] [Full Text]

Inhaler errors in the CRITIKAL study: type, frequency, and association with asthma outcomes

Price DB, Román-Rodríguez M, McQueen RB, Bosnic-Anticevich S, Carter V, et al.
J Allergy Clin Immunol Pract 2017; 5(4): 1071-81.e9.
[PubMed] [Full Text]

Comparative effectiveness of step-up therapies in children with asthma prescribed inhaled corticosteroids: a historical cohort study

Murray CS, Thomas M, Richardson K, Price DB, Turner SW.
J Allergy Clin Immunol Pract 2017.
[PubMed] [Full Text]

An evaluation of exact matching and propensity score methods as applied in a comparative effectiveness study of inhaled corticosteroids in asthma

Burden A, Roche N, Miglio C, Hillyer EV, Postma DS, et al.
Pragmat Obs Res 2017; 8: 15-30.
[PubMed] [Full Text]

Identifying risk of future asthma attacks using UK medical record data: a Respiratory Effectiveness Group initiative

Blakey JD, Price DB, Pizzichini E, Popov TA, Dimitrov BD, et al.
J Allergy Clin Immunol 2016.
[PubMed] [Full Text]

Asthma-related outcomes in patients initiating extrafine ciclesonide or fine-particle inhaled corticosteroids

Postma DS, Dekhuijzen R, van der Molen T, Martin RJ, van Aalderen W, Roche N, et al.
Allergy Asthma Immunol Res 2017; 9(2): 116-25.
[PubMed] [Full Text]

Real-life outcomes for patients with asthma prescribed spacers for use with either extrafine- or fine-particle inhaled corticosteroids

Guilbert TW, Colice G, Grigg J, van Aalderen W, Martin RJ, et al; in collaboration with the Respiratory Effectiveness Group
J Allergy Clin Immunol Pract 2017; 5(4): 1040-1049.e4.
[PubMed] [Full Text]

Long-acting β-agonist in combination or separate inhaler as step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids

Turner S, Richardson K, Murray C, Thomas M, Hillyer EV, et al; Respiratory Effectiveness Group
J Allergy Clin Immunol Pract 2017; 5(1): 99–106.e3.
[PubMed] [Full Text]

Cost comparison of asthma treatments in 12-week study: caution about matching and short observational follow-up

Price DB, van Boven JFM, Law LM, Cifra A, McQueen RB
Multidiscip Respir Med 2016; 11: 39.
[PubMed] [Full Text]

Historical cohort study examining comparative effectiveness of albuterol inhalers with and without integrated dose counter for patients with asthma or chronic obstructive pulmonary disease

Price DB, Rigazio A, Small MB, Ferro TJ
J Asthma Allergy 2016; 9: 145-54.
[PubMed] [Full Text]

Inappropriate asthma therapy—a tale of two countries: a parallel population-based cohort study

Belhassen M, Nibber A, Van Ganse E, Ryan D, Langlois C, Appiagyei F, et al.
NPJ Prim Care Respir Med 2016; 26: 16076.
[PubMed] [Full Text]

Effectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the Netherlands

van der Molen T, Postma DS, Martin RJ, Herings RM, Overbeek JA, Thomas V, et al.
BMC Pulm Med 2016; 16(1): 80.
[PubMed] [Full Text]

Cost-effectiveness of asthma step-up therapy as an increased dose of extrafine-particle inhaled corticosteroid or add-on long-acting beta2-agonist

Roche N, ColiceG, Israel E, Martin RJ, Dorinsky PM, Postma DS, et al.
Pulm Ther 2016; 2: 73-89.
[Full Text]

Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler

Price DB, Colice G , Israel E , Roche N , Postma DS , Guilbert TW, et al.
ERJ Open Res 2016; 2(2).
[PubMed] [Full Text]

Reply [Inhaled corticosteroids for asthma therapy in young children: does aerosol particle size matter?]

Van Aalderen WMC, Grigg J, Guilbert TW, Roche N, Colice G, Postma DS, et al.
J Allergy Clin Immunol Pract 2016; 4(2): 372-3.
[Full Text]

Comparison of serious inhaler technique errors made by device-naïve patients using three different dry powder inhalers: a randomised, crossover, open-label study

Chrystyn H, Price DB, Molimard M, Haughney J, Bosnic-Anticevich S, Lavorini F, et al.
BMC Pulm Med 2016; 16(1):12.
[PubMed] [Full Text]

Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice

Price D, Wilson AM, Chisholm A, Rigazio A, Burden A, Thomas M, et al.
J Asthma Allergy 2016; 9: 1-12.
[PubMed] [Full Text]

Characteristics of patients making serious inhaler errors with a dry powder inhaler and association with asthma-related events in a primary care setting

Westerik JA, Carter V, Chrystyn H, Burden A, Thompson SL, Ryan D, et al.
J Asthma 2016; 53(3): 321-9.
[PubMed] [Full Text]

Inhaled corticosteroid dose-response on blood eosinophils in asthma – Authors’ reply

Price DB, Pavord ID, Thomas M, Corrigan CJ, Wilson AM, Hillyer EV, et al.
Lancet Respir Med 2016; 4(1): e1-2.
[PubMed] [Full Text]

Concept review of dry powder inhalers: correct interpretation of published data

Price D, Chrystyn H
Multidiscip Respir Med 2015; 10:36.
[PubMed] [Full Text]

Small-particle inhaled corticosteroid as first-line or step-up controller therapy in childhood asthma

van Aalderen WM, Grigg J, Guilbert TW, Roche N, Israel E, Martin RJ, et al.
J Allergy Clin Immunol Pract 2015; 3(5): 721-31.e16.
[PubMed] [Full Text]

Initial step-up treatment changes in asthmatic children already prescribed inhaled corticosteroids: a historical cohort study

Turner SW, Richardson K, Burden A, Thomas M, Murray C, Price D
NPJ Prim Care Respir Med 2015; 25: 15041.
[PubMed] [Full Text]

Increased dose of inhaled corticosteroid versus add-on long-acting β-agonist for step-up therapy in asthma

Israel E, Roche N, Martin RJ, Colice G, Dorinsky PM, Postma DS, et al.
Ann Am Thorac Soc 2015; 12(6): 798-806.
[PubMed] [Full Text]

Long-acting muscarinic antagonist use in adults with asthma: real-life prescribing and outcomes of add-on therapy with tiotropium bromide

Price D, Kaplan A, Jones R, Freeman D, Burden A, Gould S, et al.
J Asthma Allergy 2015; 8: 1-13.
[PubMed] [Full Text]

Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study

Price DB, Rigazio A, Campbell JD, Bleecker ER, Corrigan CJ, Thomas M, et al.
Lancet Respir Med 2015; 3(11): 849–58.
[PubMed] [Full Text]

Differential effects of inhaled corticosteroids in smokers/ex-smokers and nonsmokers with asthma

Roche N, Postma DS, Colice G, Burden A, Guilbert TW, Israel E, et al.
Am J Respir Crit Care Med 2015; 191(8): 960-4.
[PubMed] [Full Text]

Cost-effectiveness of initiating extrafine- or standard size-particle inhaled corticosteroid for asthma in two health-care systems: a retrospective matched cohort study

Martin RJ, Price D, Roche N, Israel E, van Aalderen WMC, Grigg J, et al.
NPJ Prim Care Respir Med 2014; 24: 14081.
[PubMed] [Full Text]

Fluticasone propionate/formoterol fumarate in fixed-dose combination for the treatment of asthma

Price D, Hillyer EV
Expert Rev Respir Med 2014; 8(3): 275-91.
[PubMed] [Full Text]

Switching patients from other inhaled corticosteroid devices to the Easyhaler®: historical, matched-cohort study of real-life asthma patients

Price D, Thomas V, von Ziegenweidt J, Gould S, Hutton C, King C
J Asthma Allergy 2014; 10(7): 31-51.
[PubMed] [Full Text]

Using fractional exhaled nitric oxide (FeNO) to diagnose steroid-responsive disease and guide asthma management in routine care

Price D, Ryan D, Burden A, Von Ziegenweidt J, Gould S, Freeman D, et al.
Clin Transl Allergy 2013; 3(1): 37.
[PubMed] [Full Text]

Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients

Price D, Small I, Haughney J, Ryan D, Gruffydd-Jones K, Lavorini F, et al.
Prim Care Respir J 2013; 22(4): 439-48.
[PubMed] [Full Text]

Real-life comparison of beclometasone dipropionate as an extrafine- or larger-particle formulation for asthma

Price D, Thomas M, Haughney J, Lewis RA, Burden A, von Ziegenweidt J, et al.
Respir Med 2013; 107(7): 987-1000.
[PubMed] [Full Text]

Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone

Colice G, Martin R, Israel E, Roche N, Barnes N, Burden A, et al.
J Allergy Clin Immunol 2013; 132(1): 45-54.
[PubMed] [Full Text]

Effect of inhaled corticosteroid therapy step-down and dosing regimen on measures of asthma control

Price D, Chisholm A, Hillyer EV, Burden A, von Ziegenweidt J, Svedsater H, et al.
J Allergy Ther 2013; 4(1): 126.

[Full Text]

Efficacy versus effectiveness trials: informing guidelines for asthma management

Price D, Hillyer E, van der Molen T
Curr Opin Allergy Clin Immunol 2013; 13(1): 50-7.
[PubMed] [Full Text]

Real-life asthma strategies: the missing piece in the jigsaw

Price D, Bjermer L, Haughney J, Roche N, Bousquet J, Hillyer EV, et al.
Treatment Strategies – Respiratory 2013; 3(2): 37-46.

Effectiveness of same versus mixed asthma inhaler devices: a retrospective observational study in primary care

Price D, Chrystyn H, Kaplan A, Haughney J, Román-Rodríguez M, Burden A, et al.
Allergy Asthma Immunol Res 2012; 4(4): 184-91.
[PubMed] [Full Text]

Asthma control with extrafine-particle hydrofluoroalkane-beclometasone vs. large-particle chlorofluorocarbon-beclometasone: a real-world observational study

Barnes N, Price D, Colice G, Chisholm A, Dorinsky P, Hillyer EV, et al.
Clin Exp Allergy 2011; 41(11): 1521-32.
[PubMed] [Full Text]

Reassessing the evidence hierarchy in asthma: evaluating comparative effectiveness

Price D, Chisholm A, van der Molen T, Roche N, Hillyer EV, Bousquet J
Curr Allergy Asthma Rep 2011; 11(6): 526-38.
[PubMed] [Full Text]

Device type and real-world effectiveness of asthma combination therapy: an observational study

Price D, Roche N, Christian Virchow J, Burden A, Ali M, Chisholm A, et al.
Respir Med 2011; 105(10): 1457-66.
[PubMed] [Full Text]

Current control and future risk in asthma management

Sims EJ, Price D, Haughney J, Ryan D, Thomas M
Allergy Asthma Immunol Res 2011; 3(4): 217-25.
[PubMed] [Full Text]

Effectiveness of inhaler types for real-world asthma management: retrospective observational study using the GPRD

Price D, Haughney J, Sims E, Ali M, Von Ziegenweidt J, Hillyer EV, et al.
J Asthma Allergy 2011; 4: 37-47.
[PubMed] [Full Text]

The authors reply [Leukotriene antagonists in asthma]

Price D, Juniper EF, Hillyer EV
N Engl J Med 2011; 365(3): 273-4.
[Full Text]

Leukotriene antagonists as first-line or add-on asthma-controller therapy

Price D, Musgrave SD, Shepstone L, Hillyer EV, Sims EJ, Gilbert RF, et al.
N Engl J Med 2011; 364(18): 1695-707.
[PubMed] [Full Text]

Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: a real-world observational study

Price D, Martin RJ, Barnes N, Dorinsky P, Israel E, Roche N, et al.
J Allergy Clin Immunol 2010; 126(3): 511-8.e10.
[PubMed] [Full Text]

Observational study comparing intranasal mometasone furoate with oral antihistamines for rhinitis and asthma

Price D, Kemp L, Sims E, von Ziegenweidt J, Navaratnam P, Lee AJ, et al.
Prim Care Respir J 2010; 19(3): 266-73.
[PubMed] [Full Text]

Cost-effectiveness analysis of corticosteroid inhaler devices in primary care asthma management: a real world observational study

Kemp L, Haughney J, Barnes N, Sims E, von Ziegenweidt J, Hillyer EV, et al.
Clinicoecon Outcome Res 2010; 2: 75-85.
[PubMed] [Full Text]

Cost effectiveness of leukotriene receptor antagonists versus long-acting beta-2 agonists as add-on therapy to inhaled corticosteroids for asthma: a pragmatic trial

Wilson EC, Price D, Musgrave SD, Sims EJ, Shepstone L, Murdoch J, et al.
Pharmacoeconomics 2010; 28(7): 597-608.
[PubMed] [Full Text]

Cost effectiveness of leukotriene receptor antagonists versus inhaled corticosteroids for initial asthma controller therapy: a pragmatic trial

Wilson EC, Sims EJ, Musgrave SD, Shepstone L, Blyth A, Murdoch J, et al.
Pharmacoeconomics 2010; 28(7): 585-95.
[PubMed] [Full Text]

Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control

Thomas M, Price D, Chrystyn H, Lloyd A, Williams A, von Ziegenweidt J
BMC Pul Med 2009; 9: 1.
[PubMed] [Full Text]

High-dose inhaled corticosteroids versus add-on long-acting beta-agonists in asthma: an observational study

Thomas M, von Ziegenweidt J, Lee AJ, Price D
J Allergy Clin Immunol 2009; 123(1):116-21.e10.
[PubMed] [Full Text]

Prescribing trends in asthma: a longitudinal observational study

Turner SW, Thomas M, von Ziegenweidt J, Price D
Arch Dis Child 2009; 94(1): 16-22.
[PubMed] [Full Text]

COPD

The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study

Jones R, Martin J, Thomas V, Skinner D, Marshall J, et al.
Int J Chron Obstruct Pulmon Dis 2017; 12: 2445-2454.
[PubMed] [Full Text]

Blood eosinophil count and exacerbation risk in patients with COPD

Kerkhof M, Sonnappa S, Postma DS, Brusselle G, Agustí A, et al.
Eur Respir J 2017; 50(1): 1700761.
[Full Text]

Risk of pneumonia in obstructive lung disease: a real-life study comparing extra-fine and fine-particle inhaled corticosteroids

Sonnappa S, Martin R, Israel E, Postma D, van Aalderen W, et al.
PLoS One 2017; 12(6): e0178112.
[PubMed] [Full Text]

Does co-payment for inhaler devices affect therapy adherence and disease outcomes? A historical, matched cohort study

Voorham J, Vrijens B, van Boven JF, Ryan D, Miravitlles M, et al.
Pragmat Obs Res 2017; 8: 31-41.
[PubMed] [Full Text]

Ipratropium/Salbutamol comparator versus originator for chronic obstructive pulmonary disease exacerbations: US observational cohort study using the Clinformatics™ health claims database

Thomas V, Gefen E, Gopalan G, Mares R, McDonald R, et al.
Pulm Ther 2017; 3(1): 187-205.
[Full Text]

The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes

Bosnic-Anticevich S, Chrystyn H, Costello RW, Dolovich MB, Fletcher MJ, et al.
Int J Chron Obstruct Pulmon Dis 2017; 12: 59-71.
[PubMed] [Full Text]

It is important to distinguish between HFrEF and HFpEF when interpreting these data

Lipworth B, Skinner D, Devereux G, Thomas V, Ling JZJ, Martin J, et al.
Heart 2016; 102(23): 1934.
[PubMed] [Full Text]

First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis

Price D, Miravitlles M, Pavord I, Thomas M, Wedzicha J, et al.
NPJ Prim Care Respir Med 2016; 26: 16061.
[PubMed] [Full Text]

Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: effect of drug, dose, and device

Dekhuijzen PNR, Batsiou M, Bjermer L, Bosnic-Anticevich S, Chrystyn H, Papi A, et al.
Respir Med 2016; 120: 54-63.
[PubMed] [Full Text]

Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy

Halpin DMG, Kerkhof M, Soriano JB, Mikkelsen H, Price DB
Respir Res 2016; 17(1): 120.
[PubMed] [Full Text]

Metabolic effects associated with ICS in patients with COPD and comorbid type 2 diabetes: a historical matched cohort study

Price DB, Russell R, Mares R, Burden A, Skinner D, Mikkelsen H, et al.
PLoS One 2016; 11(9): e0162903.
[PubMed] [Full Text]

Historical cohort study examining comparative effectiveness of albuterol inhalers with and without integrated dose counter for patients with asthma or chronic obstructive pulmonary disease

Price DB, Rigazio A, Small MB, Ferro TJ
J Asthma Allergy 2016; 9: 145-54.
[PubMed] [Full Text]

Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease

Lipworth B, Skinner D, Devereux G, Thomas V, Ling JZJ, Martin J, et al.
Heart 2016; 102(23): 1909-14.
[PubMed] [Full Text]

Comparison of serious inhaler technique errors made by device-naïve patients using three different dry powder inhalers: a randomised, crossover, open-label study

Chrystyn H, Price DB, Molimard M, Haughney J, Bosnic-Anticevich S, Lavorini F, et al.
BMC Pulm Med 2016; 16(1):12.
[PubMed] [Full Text]

Changes in initial COPD treatment choice over time and factors influencing prescribing decisions in UK primary care: in UK primary care: a real-world, retrospective, observational

Gruffydd-Jones K, Brusselle G, Jones R, Miravitlles M, Baldwin M, Stewart R, et al.
NPJ Prim Care Respir Med 2016; 26: 16002.
[PubMed] [Full Text]

Concept review of dry powder inhalers: correct interpretation of published data

Price D, Chrystyn H
Multidiscip Respir Med 2015; 10:36.
[PubMed] [Full Text]

Predicting frequent COPD exacerbations using primary care data

Kerkhof M, Freeman D, Jones R, Chisholm A, Price DB; Respiratory Effectiveness Group
Int J Chron Obstruct Pulmon Dis 2015; 10: 2439-50.
[PubMed] [Full Text]

Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD

Postma DS, Roche N, Colice G, Israel E, Martin RJ, van Aalderen WMC, et al.
Int J Chron Obstruct Pulmon Dis 2014; 9: 1163-86.
[PubMed] [Full Text]

Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns

Price D, West D, Brusselle G, Gruffydd-Jones K, Jones R, Miravitlles M, et al.
J Chron Obstruct Pulmon Dis 2014; 9: 889-904.
[PubMed] [Full Text]

Adjunctive treatment with oral AKL1, a botanical nutraceutical, in chronic obstructive pulmonary disease

Brockwell C, Ampikaipakan S, Sexton D, Price D, Freeman D, Thomas M, et al.
Int J Chron Obstruct Pulmon Dis 2014; 9: 715-21.
[PubMed] [Full Text]

Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort

Jones R, Price D, Ryan D, Sims E, von Ziegenweidt J, Mascarenhas L, et al.
Lancet Respir Med 2014; 2(4): 267-76.
[PubMed] [Full Text]

Characteristics of patients preferring once-daily controller therapy for asthma and COPD: a retrospective cohort study

Price D, Lee A, Sims EJ, Kemp L, Hillyer EV, Chisholm A, et al.
Prim Care Respir J 2013; 22(2): 161-8.
[PubMed] [Full Text]

Spirometry: an essential tool for screening, case-finding, and diagnosis of COPD

Sims EJ, Price D
Prim Care Respir J 2012; 21(2): 128-30.
[PubMed] [Full Text]

The use of roflumilast in COPD: a primary care perspective

Price D, Chisholm A, Ryan D, Crockett A, Jones R
Prim Care Respir J 2010; 19(4): 342-51.
[PubMed] [Full Text]

Improving clinician-patient communication in asthma: the HARP project

Haughney J, Sims E, Holohan J, Ryan D, Price D
Allergy 2010; 65(4): 413-4.
[PubMed] [Full Text]

Allergy & Immunology

Seasonal patterns of oral antihistamine and intranasal corticosteroid purchases from Australian community pharmacies: a retrospective observational study

Carney AS, Price DB, Smith PK, Harvey R, Kritikos V, et al.
Pragmat Obs Res 2017; 8: 157-165.
[PubMed] [Full Text]

UK prescribing practices as proxy markers of unmet need in allergic rhinitis: a retrospective observational study

Price DB, Scadding G, Bachert C, Saleh H, Nasser S, Carter V, et al.
NPJ Prim Care Respir Med 2016; 26:16033.
[PubMed] [Full Text]

Current controversies and challenges in allergic rhinitis management

Price D, Smith P, Hellings P, Papadopoulos N, Fokkens W, Muraro A, et al.
Expert Rev Clin Immunol 2015; 11(11): 1205-17.
[PubMed] [Full Text]

Observational study comparing intranasal mometasone furoate with oral antihistamines for rhinitis and asthma

Price D, Kemp L, Sims E, von Ziegenweidt J, Navaratnam P, Lee AJ, et al.
Prim Care Respir J 2010; 19(3): 266-73.
[PubMed] [Full Text]

Dementia

Excess costs associated with possible misdiagnosis of Alzheimer’s disease among patients with vascular dementia in a UK CPRD population

Happich M, Kirson NY, Desai U, King S, Birnbaum HG, Reed C, et al.
J Alzheimers Dis 2016; 53(1): 171–83.
[PubMed] [Full Text]

Cardiovascular Disease

Cardiovascular risks in smokers treated with nicotine replacement therapy: a historical cohort study

Dollerup J, Vestbo J, Murray-Thomas T, Kaplan A, Martin RJ, et al.
Clin Epidemiol 2017; 9: 231-43.
[PubMed] [Full Text]

Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease

Lipworth B, Skinner D, Devereux G, Thomas V, Ling JZJ, Martin J, et al.
Heart 2016.
[PubMed] [Full Text]

Metabolic Disease

Metabolic effects associated with ICS in patients with COPD and comorbid type 2 diabetes: a historical matched cohort study

Price DB, Russell R, Mares R, Burden A, Skinner D, Mikkelsen H, et al.
PLoS One 2016; 11(9): e0162903.
[PubMed] [Full Text]